CD8A and non-small cell lung carcinoma: We analyzed the relationship between the immune cell infiltration level and progression-free survival (PFS) in 43 advanced NSCLC patients treated with anti-PD-1 antibody monotherapy in the GSE190265 dataset by gene set variation analysis (GSVA) and showed that higher B cell signature and CD4 signature correlated with better PFS (Fig. 7c, d), and higher memory and effector CD8 signatures in tumors were significantly associated with longer PFS in patients (Fig. 7e, f).